PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
9.89
P/E exceeding 1.5x Medical - Pharmaceuticals median of 5.57. Michael Burry would check for market euphoria. Scrutinize growth expectations.
1.08
P/S less than half the Medical - Pharmaceuticals median of 5.83. Walter Schloss would verify if this discount reflects fixable issues. Check margins versus peers.
2.05
P/B 1.1-1.25x Medical - Pharmaceuticals median of 1.67. John Neff would demand superior ROE to justify premium.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.05
Fair value ratio 1.1-1.25x Medical - Pharmaceuticals median of 1.67. John Neff would demand superior metrics to justify premium.
2.53%
Earnings yield exceeding 1.5x Medical - Pharmaceuticals median of 0.55%. Joel Greenblatt would investigate if high yield reflects hidden value.
No Data
No Data available this quarter, please select a different quarter.